Evidence map›Paper›PMID 40225971›Full record

ReviewAmerican journal of translational research2025

Advances in diagnosis and treatment of lymphoma-associated hemophagocytic syndrome.

Fuli Fan, Jian Liu, Shanshan Liu, Yujie Xu, Xiaolin Wang, Yuting Yan, Zhiqun Zhang

Abstract readReview
In one paragraph

Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fuli FanDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Jian LiuDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Shanshan LiuDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Yujie XuDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Xiaolin WangDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Yuting YanDepartment of Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao 266000, Shandong, China.
Zhiqun ZhangDepartment of Oncology, Tongliao People's Hospital Tongliao 028000, Inner Mongolia Autonomous Region, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic syndrome (HPS) is a rare clinical disorder characterized by persistent and ineffective activation of the immune system, leading to a severe systemic inflammatory response. Lymphoma-associated hemophagocytic syndrome (LAHS) refers to HPS caused either by lymphoma itself or by immunosuppression during lymphoma chemotherapy at present, there is no standardized consensus on the diagnosis and treatment of LAHS, both domestically and internationally. After remission induced by combination chemotherapy, hematopoietic stem cell transplantation (HSCT) is a commonly used treatment approach. This paper reviews the latest advancements in the diagnosis and treatment of LAHS, providing a reference for its clinical management.

Indexed as

diagnosisLymphoma-associated hemophagocytic syndromepathogenesisprognosistreatment

Identifiers

PMID40225971
PMCPMC11982887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.